Loading
Sarepta Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Chambers Michael Andrew, was filed 20 Aug 2024.
Insider Decl.
602
Thresholds
n/a
Buy Volume
€42M
40 ops. · all time
Sell Volume
€140M
99 ops. · all time
Who traded when
BuySaleClaude Nicaise1 sale
Hans Lennart Rudolf Wigzell1 sale
Ian Michael Estepan1 sale
Kathryn Jean Boor1 sale
Stephen Mayo1 sale
Since the insiders bought
- -86.0%Entry US$143.45 · Close at T+365 US$20.06
- +54.3%Entry US$82.93 · Close at T+365 US$127.97
- +54.3%Entry US$82.93 · Close at T+365 US$127.97
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Sarepta Therapeutics, Inc. Hold (neutral), based on 22 analysts. Average price target: US$21.64.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,503 of 26,248 companies
22.3
score / 100
Value10
Quality35
FCF yld-16%
Earn yld-36%
EV/EBITDA·
ROE-9.5%
Gross mgn62%
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$18.56
Analyst consensus
22 analystsHold
US$5.00Target US$21.64(+17%)US$38.00
Income statement
RevenueUS$2.2B
Gross profitUS$1.4B62% margin
EBITDA-US$619.6M-28% margin
Net income-US$713.4M-6.9% margin
Valuation
PER (trailing)46.9x
PER (forward)7.6x
P/Book1.3x
Beta0.38
Balance sheet & cash
Market capUS$2B
Total debtUS$1B
Free Cash Flow-US$315.3M
Debt / Equity70%
Profitability & ownership
ROE-9.5%
ROA-1.1%
% insiders4.9%
% institutions103.4%
Last declaration on 8 September 2026
Declarations602 total
21,423 shares@ US$22.220.023% mcap13.3% of flowCommon StockSEC:0001193125-26-385536:0
22,025 shares@ US$22.220.024% mcap62.6% of flowCommon StockSEC:0001193125-26-385541:0
13,272 shares@ US$22.220.014% mcap93.2% of flowCommon StockSEC:0001193125-26-385545:0
24,799 shares@ US$22.220.028% mcap9.2% of flowCommon StockSEC:0001193125-26-385544:0
756,104 sharesCommon StockSEC:0001193125-26-324445:0
16,875 sharesCommon StockSEC:0001193125-26-260257:0
16,875 sharesCommon StockSEC:0001193125-26-260245:0
16,875 sharesCommon StockSEC:0001193125-26-260255:0
16,875 sharesCommon StockSEC:0001193125-26-260246:0
16,875 sharesCommon StockSEC:0001193125-26-260263:0
256 shares@ US$17.031.4% of flowCommon StockSEC:0001193125-26-106706:0
948 shares@ US$17.030.5% of flowCommon StockSEC:0001193125-26-106703:0
7,239 shares@ US$17.0219.3% of flowCommon StockSEC:0001193125-26-106701:0
974 shares@ US$17.032.1% of flowCommon StockSEC:0001193125-26-106697:0
1,097 shares@ US$17.030.6% of flowCommon StockSEC:0001193125-26-106710:0
895 shares@ US$16.950.3% of flowCommon StockSEC:0001193125-26-102703:1
583 shares@ US$16.950.2% of flowCommon StockSEC:0001193125-26-102701:1
346 shares@ US$16.950.7% of flowCommon StockSEC:0001193125-26-102708:1
113 shares@ US$16.950.6% of flowCommon StockSEC:0001193125-26-102710:1
484 shares@ US$16.951.1% of flowCommon StockSEC:0001193125-26-102708:0
504 shares@ US$16.950.2% of flowCommon StockSEC:0001193125-26-102703:0
1,036 shares@ US$16.950.6% of flowCommon StockSEC:0001193125-26-102701:0
162 shares@ US$16.950.9% of flowCommon StockSEC:0001193125-26-102710:0
3,301 shares@ US$16.200.9% of flowCommon StockSEC:0001193125-26-089432:1
875 shares@ US$16.200.2% of flowCommon StockSEC:0001193125-26-089432:2
25 of 602 declarations
About Sarepta Therapeutics, Inc.
The two largest sales at Sarepta Therapeutics, Inc. come from Sandesh Mahatme (EVP, CFO & CBO): EUR 14,024,155 on December 13, 2019 and EUR 12,049,131 on October 24, 2018. David T. Howton (EVP, General Counsel) sold EUR 8,751,073 on December 13, 2019. In all, 97 sales represent EUR 139 million (median EUR 473,528), against 38 purchases worth EUR 39.6 million (median EUR 700,228), or 28% purchases among open-market trades.
Michael Andrew Chambers, a director, bought EUR 4,301,234 on August 19, 2022, EUR 3,156,237 on September 14, 2022 and EUR 3,054,758 on August 10, 2023. From August 12 to September 9, 2019, four insiders bought EUR 3,135,436. Across the full history, 14 purchase filings are classed as clustered.
Read moreShow less
This US healthcare company, valued at USD 1.87 billion and 4.9% held by insiders, has 553 filings from 32 filers, including 260 grants and 149 option exercises. Annual volume peaks at 85 in 2019, with 30 in 2022 and 74 in 2024. The last twelve months have 31 filings, 2 of them sales. For 28 purchases, the stored 90-day result has a median of 0.1%, with 50% of results positive (recorded past, not a forecast).
